Stay updated on PAAP for Pralsetinib in NSCLC and MTC Clinical Trial
Sign up to get notified when there's something new on the PAAP for Pralsetinib in NSCLC and MTC Clinical Trial page.

Latest updates to the PAAP for Pralsetinib in NSCLC and MTC Clinical Trial page
- Check4 days agoNo Change Detected
- Check18 days agoChange DetectedUpdated version to v3.2.0 and removed a specific resource topic (Medullary thyroid carcinoma) from the Genetic and Rare Diseases Information Center resources; added a government operating-status notice.SummaryDifference6%

- Check26 days agoChange DetectedRenamed a medical condition term (Medullary thyroid gland carcinoma → Medullary thyroid carcinoma) and updated the revision/version to v3.1.0.SummaryDifference0.2%

- Check40 days agoChange DetectedPage revision updated from v3.0.1 to v3.0.2, and the 'Back to Top' element was removed.SummaryDifference0.3%

- Check47 days agoChange DetectedThe web page has been updated from version v3.0.0 to v3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.SummaryDifference0.3%

- Check54 days agoChange DetectedThe web page has undergone significant updates, including the addition of new medical terms and conditions related to various types of carcinomas and neoplasms, as well as the facility name and location. Notably, the previous version's references to specific locations and certain cancer-related topics have been removed.SummaryDifference6%

- Check69 days agoChange DetectedThe web page has been updated from version v2.16.11 to v2.16.12.SummaryDifference0.1%

Stay in the know with updates to PAAP for Pralsetinib in NSCLC and MTC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PAAP for Pralsetinib in NSCLC and MTC Clinical Trial page.